Compare Neurocrine Biosciences Inc (NBIX) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Royal Caribbean Cruises Ltd — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Royal Caribbean Cruises Ltd trades at $261.61 (market cap $70.74B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 4.5× Neurocrine Biosciences Inc's market cap, and Royal Caribbean Cruises Ltd pays a 2.27% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | RCL | |
|---|---|---|
Market Cap | $15.77B | $70.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $350.23 |
52-Week Low | $123.10 | $246.71 |
Enterprise Value | $15.78B | $93.38B |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Royal Caribbean (RCL) trades at $264.5, down 0.26% on the day, with technical indicators showing a bearish trend near key support at $261. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $4.21 vs. $3.98, revenue growth to $17.93B in 2025, and robust profitability margins. Recent news highlights dividend declarations and institutional buying interest despite oil price concerns impacting cruise stocks.
The outlook remains positive with analyst consensus price target of $367.83 suggesting 39% upside, supported by earnings momentum and institutional accumulation. Key risks include oil price volatility affecting fuel costs and competitive pressures in the cruise industry. The stock presents a growth opportunity with solid fundamentals but requires monitoring of macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
